ArticlePharmacoEconomics2017
The Implementation of Managed Entry Agreements in Central and Eastern Europe: Findings and Implications.
Article in PharmacoEconomics, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 53 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
53 citing papers in PubMed, 1 synthesis or guideline pooled it, 119 citations in OpenAlex.
- The Use of Risk-Sharing Contracts in Healthcare: Theoretical and Empirical Assessments.PharmacoEconomics · 2019Pooled it
- Governing AI for Pharmacovigilance in Low-Income Countries: Systems Perspective.Journal of medical Internet research · 2026Article
- Balancing Innovation and Access: Insights from AIM's Fair Pricing Model and Its Current and Future Applications.PharmacoEconomics · 2026Article
- Managed Entry Agreements for Pharmaceutical Products in Three Maghreb Countries: Payer and Supplier Perspectives.Journal of market access & health policy · 2025Article
- Systematic Literature Review and Network Meta-Analysis of Clinical Efficacy and Safety of Topical Treatments for Patients with Atopic Dermatitis.Dermatology and therapy · 2025Review
- The value-for-money assessment and funding arrangements for high-priced drugs in an era of uncertainty: a comparative analysis of national health technology assessment agencies in South Korea, England, Australia, and Canada.BMC health services research · 2025Article
- Delayed access to innovative medicines in Romania: a comprehensive analysis of the reimbursement processes (2015-2024).Frontiers in public health · 2025Article
- Stakeholder Insights into Czech Performance-Based Managed Entry Agreements: Potential for Transformative Change in Pharmaceutical Access?Healthcare (Basel, Switzerland) · 2024Article
- How Managed Entry Agreements Influence the Patients' Affordability to Biological Medicines-Bulgarian Example.Healthcare (Basel, Switzerland) · 2023Article
- Opportunities and Threats of the Legally Facilitated Performance-Based Managed Entry Agreements in Slovakia: The Early-Adoption Perspective.Healthcare (Basel, Switzerland) · 2023Article
- The role of clinical trials in the sustainability of the Italian national health service cancer drug expenditure.European journal of hospital pharmacy : science and practice · 2023Article
- Pricing and reimbursement mechanisms for advanced therapy medicinal products in 20 countries.Frontiers in pharmacology · 2023Article
- Introduction of managed entry agreements in Korea: Problem, policy, and politics.Frontiers in pharmacology · 2023Article
- When Reality Does Not Meet Expectations-Experiences and Perceived Attitudes of Dutch Stakeholders Regarding Payment and Reimbursement Models for High-Priced Hospital Drugs.International journal of environmental research and public health · 2022Article
- How Do Iranian Stakeholders Think About Pharmaceutical Managed Entry Agreements?Iranian journal of pharmaceutical research : IJPR · 2022Article
- Assessing, Pricing and Funding Point-of-Care Diagnostic Tests for Community-Acquired Acute Respiratory Tract Infections-Overview of Policies Applied in 17 European Countries.Antibiotics (Basel, Switzerland) · 2022Article
- Budget cap and pay-back model to control spending on medicines: A case study of Bulgaria.Frontiers in public health · 2022Article
- Outcome-based reimbursement in Central-Eastern Europe and Middle-East.Frontiers in medicine · 2022Article
- Delayed payment schemes in Central-Eastern Europe and Middle-East.Frontiers in medicine · 2022Article
- Challenges and Opportunities With Routinely Collected Data on the Utilization of Cancer Medicines. Perspectives From Health Authority Personnel Across 18 European Countries.Frontiers in pharmacology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
24 authors at 16 institutions in 13 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundManaged entry agreements (MEAs) are a set of instruments to facilitate access to new medicines. This study surveyed the implementation of MEAs in Central and Eastern Europe (CEE) where limited comparative information is currently available.
methodWe conducted a survey on the implementation of MEAs in CEE between January and March 2017.
resultsSixteen countries participated in this study. Across five countries with available data on the number of different MEA instruments implemented, the most common MEAs implemented were confidential discounts (n = 495, 73%), followed by paybacks (n = 92, 14%), price-volume agreements (n = 37, 5%), free doses (n = 25, 4%), bundle and other agreements (n = 19, 3%), and payment by result (n = 10, >1%). Across seven countries with data on MEAs by therapeutic group, the highest number of brand names associated with one or more MEA instruments belonged to the Anatomical Therapeutic Chemical (ATC)-L group, antineoplastic and immunomodulating agents (n = 201, 31%). The second most frequent therapeutic group for MEA implementation was ATC-A, alimentary tract and metabolism (n = 87, 13%), followed by medicines for neurological conditions (n = 83, 13%).
conclusionsExperience in implementing MEAs varied substantially across the region and there is considerable scope for greater transparency, sharing experiences and mutual learning. European citizens, authorities and industry should ask themselves whether, within publicly funded health systems, confidential discounts can still be tolerated, particularly when it is not clear which country and party they are really benefiting. Furthermore, if MEAs are to improve access, countries should establish clear objectives for their implementation and a monitoring framework to measure their performance, as well as the burden of implementation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.